Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. (DYN) reported that its Head of R&D and CMO, Douglas Kerr, received an award of 8,000 restricted stock units (RSUs) and a stock option covering 12,000 shares on October 20, 2026. Each RSU represents the right to receive one common share upon vesting, and the option has an exercise price of $16.27 per share. Kerr's reported common-stock holdings following the award were 170,564 shares, including 133,126 unvested RSUs.
Dyne Therapeutics, Inc. director Brian S. Posner purchased 2,500 shares of common stock at $16 per share on October 2, 2026. The shares were held directly, and his reported holdings after the purchase were 27,000 shares. No Rule 10b5-1 plan is reported for the purchase.
Dyne Therapeutics, Inc. (DYN) reported additional one-year clinical data for z-basivarsen in the ACHIEVE trial for DM1. The pooled dose group included 25–26 participants from three dose regimens; only 8 of 26 received the 6.8 mg/kg registrational dose for the full 12 months. At six months, mean video hand opening time (vHOT) decreased 3.2 seconds from its 8.2-second baseline, while placebo increased 0.4 seconds.
At 12 months, the group improved from baseline by 1.2 seconds on 5xSTS, 0.3 seconds on 10MWR, 4.8% predicted on both QMT total and hand-grip scores, and 25.2% on the MDHI total score. Reported divergence from matched natural-history data applied to 10MWR and both QMT measures; MDHI was compared with an unmatched cohort, and END-DM1 did not assess 5xSTS. Safety data through April 20, 2026 identified no related serious treatment-emergent adverse events. The 71-person registrational expansion cohort had a mean baseline vHOT of 8.3 seconds, with those baseline data still blinded to treatment assignment. Topline data are expected in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.
Dyne Therapeutics, Inc. (DYN) has a notice under Rule 144 for planned sales of common stock held for the account of officer John Cox. A broker, Stifel Nicolaus & Company Inc., is named to sell 5,658 shares of common stock with an aggregate market value of $106,844.00, based on 186,746,431 shares outstanding. The notice also identifies 9,081 shares underlying Restricted Stock Units from issuer equity compensation as securities to be sold, and it lists prior sales by Cox over the past three months.
Dyne Therapeutics, Inc. (DYN) reported that officer Doug Kerr, through broker Stifel Nicolaus & Company Inc., has filed a Rule 144 notice to sell 3,000 shares of common stock on September 4, 2026, arising from Restricted Stock Units granted as equity compensation.
The notice also lists prior sales of Dyne common stock by Doug Kerr over the past three months, including 887 shares on June 16, 2026 for $16,263, 1,556 shares on August 13, 2026 for $40,892, and 3,745 shares on September 4, 2026 for $91,187.
Dyne Therapeutics, Inc. (DYN) reported that Chief Commercial Officer Johanna Friedl-Naderer sold a total of 1,085 shares of common stock on September 4 and September 8, 2026. The filing states these were automatic sales to satisfy tax withholding obligations upon vesting of restricted stock units under a Rule 10b5-1 binding contract, and are not discretionary trades. The company also reports that her equity position includes 102,966 unvested RSUs.
Dyne Therapeutics, Inc. (DYN) reported that Chief Medical Officer Douglas Kerr sold a total of 5,035 shares of common stock in two transactions on September 4 and 8, 2026. The sales were automatically executed to satisfy tax withholding obligations triggered by vesting of restricted stock units.
The automatic sales occurred under restricted stock unit agreements constituting a “binding contract” consistent with the affirmative defense under Rule 10b5-1 and are described as non-discretionary. Following these transactions, Kerr continues to hold 125,126 unvested RSUs.
Dyne Therapeutics, Inc. (DYN) reported that CEO and President John Cox sold 5,658 shares of common stock on September 8, 2026 at a weighted average price of $18.88 per share. The sale was an automatic transaction to satisfy tax withholding obligations upon vesting of restricted stock units under a pre-arranged Rule 10b5-1 binding contract, and is described as not a discretionary trade. Following this sale, Cox directly holds 357,507 shares of common stock, including 239,233 unvested RSUs, and four trusts for the benefit of his children each hold 18,000 shares indirectly.
Dyne Therapeutics, Inc. (DYN) had an officer, Doug Kerr, file a Rule 144 notice covering a planned sale of 5,000 shares of common stock through broker Stifel Nicolaus & Company. The filing also lists prior sales of Dyne common stock by Kerr over the preceding three months.
Dyne Therapeutics director Jason P. Rhodes reported indirect sales of 2,586,928 shares of Common Stock of DYN on August 13–14, 2026. The shares were sold primarily by Atlas Venture-affiliated funds at weighted average prices around $25–$26.20 per share, pursuant to a Rule 10b5-1 trading plan adopted on July 13, 2026. The footnotes state that the shares are held by various Atlas Venture funds and partnerships, and Rhodes disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest.